Back to search

Article

Stage IV Non-small Cell Lung Adenocarcinoma in Complete Response for 5 Years Post-first-line Nivolumab Immunotherapy: Are We Talking about a Cure?

2022-10-06

Abstract excerpt

<h4>Background: </h4> Metastasis of the Central Nervous System (CNS) is one of the frequently occurring complications of advanced Non-Small Cell Lung Cancer (NSCLC) and has been observed in 24-44% of patients. Patients suffering from NSCLC along with CNS metastases have a generally poor prognosis. Case Report: A 57-year-old nonalcoholic, non-diabetic, heavy smoker male patient was diagnosed with stage IV NSCLC (no...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
53bab053-2af3-549b-a27f-fb6fbb998d99
DOI
10.22541/au.166505701.10591706/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Stage IV Non-small Cell Lung Adenocarcinoma in Complete Response for 5 Years Post-first-line Nivolumab Immunotherapy: Are We Talking about a Cure?DOI 10.22541/au.166505701.10591706/v1
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.Semantic proximity
Pembrolizumab plus bevacizumab achieves long-term progression free survival in patients with lung adenocarcinoma with brain metastases: a case report and literature reviewSemantic proximity
[Annual therapeutic advances in advanced non-small cell lung cancer in 2024].Semantic proximity
[Non-small lung cancer, ECCO/ESMO congres 2017].Semantic proximity
Update in Immunotherapy for Advanced Non-small Cell Lung Cancer: Treatment Sequencing and Best ChoicesSemantic proximity
Converging Survival Trends in Non-Small Cell Lung Cancer Patients With and Without Brain Metastasis Receiving State-of-the-Art TreatmentSemantic proximity
Survival and prognostic factors in non-small cell lung cancer patients with brain metastases limited access to systemic therapySemantic proximity
Nivolumab after cyclophosphamide and doxorubicin induction chemotherapy in previously treated patients with EGFR or ALK wild type non-squamous cell non-small cell lung cancer with less than 10% of PD-L1 expressionSemantic proximity
An advanced IVB lung adenocarcinoma patient with KRAS mutations, benefited from camrelizumab combined with anti-angiogenic agents for therapy: a case reportSemantic proximity
The impact of time interval on prognosis in patients with non-small cell lung cancer brain metastases after metastases surgery: a retrospective studySemantic proximity
Evaluation of the Updated 2022 Lung-GPA in NSCLC Adenocarcinoma Patients with Brain Metastases: Analysis of Prognostic Factors in a German Clinical CohortSemantic proximity
Complete response to nivolumab in Kirsten rat sarcoma virus oncogene KRAS-G12C mutant metastatic lung adenocarcinoma: a case report.Semantic proximity
Select a neighboring publication to make it the new centre.